EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021
Methodological detailsEULAR/PReS recommendations update, EULAR standard operating procedures, systematic literature review, international expert committee
- EULAR/PReS recommendations update
- EULAR standard operating procedures
- Systematic literature review
- International expert committee
Recommendations
As issued by the authors
The National Immunisation Programmes (NIP) should be followed and assessed yearly by the treating specialist.
If possible, vaccinations should be administered prior to immunosuppressive drugs, but necessary treatment should never be postponed.
Non-live vaccines can be safely given to immunosuppressed pedAIIRD patients.
Seroprotection is mainly preserved in patients vaccinated on immunosuppression, except for high-dose GC and B-cell depleting therapies.
Live-attenuated vaccines should be avoided in immunosuppressed patients; however, the measles-mumps-rubella booster and varicella zoster virus vaccine are safe to administer to immunosuppressed patients under specific conditions.
In addition to the NIP, the non-live seasonal influenza vaccination should be strongly considered for immunosuppressed pedAIIRD patients.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →